New Orleans – We recently hosted a dinner with some of the global leaders in human genetic research. The meeting purpose was to begin discussion on: 1) the standardization of genetic; and, 2) the variability of a global human genetics project focused on both healthy populations in the study of population migration. My interest was in areas of cardiology, cancer, inflammatory conditions, infectious diseases, diabetes and obesity. Since its’ initial discovery, genomics research has progressed to the point where potential therapeutic targets of interest have been identified but few have gotten to the market. In part this is due to the the fact that the initial work is carried out on animals model and then the transferability of the work from a “model” to man has to be assured.
Secondly, the nature of an experienced and well prepared clinician to any new practices or alternatives is viewed with the apprehension that unidentified and unintended side effects could be discovered putting their patients and their reputations in jeopardy.
A third consideration is the skyrocketing cost of drug development, and the cost of development is passed on to the healthcare organization and the insurer in the process. The insurance industry is an actuarial discipline designed o monitor and mitigate risk. All of us will soon or later have to go to the doctor ffor acute or chronic medical attention or some reason — only the timing is in question. Under the P4 Medicine Model, we will likelygo sooner and be given guidance on your long term health outlook. This will result in the more data being accessed, accumulated and modeled via 3 & 4D modeling leading to quicker introduction of new medications while lessening the big concern for patient safety.
Given what we know about the human body through the early stages of genomic research, it is clear there are a number of economic development opportunities for private business to profit from. The companies that will survive and prosper the accelerated rate of new discovery will have to be near or preferably part of the innovation that is occurring. We see this already occurring in global innovation cities, like Boston, Paris, San Diego, Munich, London and others.
Every community has some role in the growing industry — it is a matter of understanding your strengths and organizing around them. That’s where we come in. We can analyze your assets, research strengths, workforce, ecosystem and develop a plan to move your community into the innovation economy.
Recently published articles of interest: